Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of &gt;2 years of follow-up

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Yves Fradet(Centre hospitalier universitaire de Québec), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), David I. Quinn(USC Norris Comprehensive Cancer Center), David J. Vaughn(University of Pennsylvania), Winald R. Gerritsen(Amsterdam UMC Location Vrije Universiteit Amsterdam), Howard Gurney(Radboud University Nijmegen), Ronald de Wit(Erasmus MC Cancer Institute), Daniel P. Petrylak(Yale University), Toni K. Choueiri(Harvard University), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Rodolfo F. Perini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), Joaquim Bellmunt(Dana-Farber Cancer Institute), J L Lee(Asan Medical Center), Andrea Necchi(Vita-Salute San Raffaele University), Stéphane Culine(Radboud University Nijmegen), M.Á. Climent(Fundación Instituto Valenciano de Oncología), Tara L. Frenkl(Merck & Co., Inc., Rahway, NJ, USA (United States)), K. Nam(Merck & Co., Inc., Rahway, NJ, USA (United States)), Cora N. Sternberg(Cornell University)

Annals of Oncology

April 26, 2019

Cited by 484